Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Cash from Financing Activities (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Cash from Financing Activities for 4 consecutive years, with $471000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities fell 74.55% to $471000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $1.2 million, a 99.4% decrease, with the full-year FY2025 number at $1.2 million, down 99.4% from a year prior.
  • Cash from Financing Activities was $471000.0 for Q4 2025 at Day One Biopharmaceuticals, down from $748000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $200.1 million in Q3 2024 to a low of $48000.0 in Q1 2024.
  • A 4-year average of $41.1 million and a median of $1.3 million in 2024 define the central range for Cash from Financing Activities.
  • Biggest YoY gain for Cash from Financing Activities was 173895.65% in 2024; the steepest drop was 99.2% in 2024.
  • Day One Biopharmaceuticals' Cash from Financing Activities stood at $1.9 million in 2022, then tumbled by 68.87% to $597000.0 in 2023, then surged by 210.05% to $1.9 million in 2024, then tumbled by 74.55% to $471000.0 in 2025.
  • Per Business Quant, the three most recent readings for DAWN's Cash from Financing Activities are $471000.0 (Q4 2025), $748000.0 (Q2 2025), and $1.9 million (Q4 2024).